Drug intelligence / Profile preview

TPI 287 + bevacizumab

Development stage: Phase 2
Lead developer: Cortice Biosciences
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

TPI 287 + bevacizumab is a combination therapy consisting of TPI 287, a blood-brain barrier penetrant microtubule stabilizer, and bevacizumab, an anti-angiogenic agent. TPI 287 is a third-generation taxane designed to evade P-glycoprotein mediated efflux, allowing it to reach high concentrations in the brain. This combination has been investigated primarily for the treatment of recurrent glioblastoma multiforme (rGBM), showing promising efficacy with median progression-free survival of 5.5 months and overall survival of 13.4 months in clinical trials.

Other names: TPI 287 plus bevacizumabTPI287 plus bevacizumabTPI-287 plus bevacizumab

Targets

VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on TPI 287 + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TPI 287 + bevacizumab.